Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war
By TOM MURPHY, AP Health Writer
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Related Articles
-
Sora app’s hyperreal AI videos ignite online trust crisis as downloads surge -
Reopening of Austin’s Coffee in Winter Park delayed due to septic issues -
How tiny drones inspired by bats could save lives in dark and stormy conditions -
American farmers welcome China’s promise to buy their soybean but this deal doesn’t solve everything -
Average long-term US mortgage rate dips to 6.17%, its lowest level in more than a year
Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. That made up over half of the drugmaker’s $17.6 billion in total sales.
Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion.
